- Kazia Therapeutics (ASX: KZA) has recently appeared across multiple leading Australian financial publications and guest speaker at a Brisbane investor event.
- Media mentions include small-cap publication, Stockhead, nabtrade and investment newsletter, the Switzer Report
- Kazia CEO James Garner also presented at the Wholesale Investor Emergence event providing an update on Kazia’s lead programs and trials.
Kazia Therapeutics (ASX: KZA) has recently appeared across multiple leading Australian financial publications as well as presenting at the recent Wholesale Investor Emergence event.
CEO James Garner featured in small-cap publication, Stockhead, in regards to a bid to form an integrated approach for new options for cancer patients following Bill Shorten’s $2.3 billion cancer funding pledge.
Kazia CEO James Garner also presented at the Wholesale Investor Emergence event in Brisbane, detailing Kazia’s expected multiple data read-outs from its international human trials during calendar 2019 and an update on Kazia’s lead program, GDC-0084 to target glioblastoma.
About Kazia Therapeutics Limited (ASX: KZA)
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.